Status:
UNKNOWN
Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis
Lead Sponsor:
University Medicine Greifswald
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multiple sclerosis (MS) is a chronic inflammatory disease with around 200.000 patients in Germany. Besides physical symptoms, cognitive resources degrade over the years. Transcranial direct current st...
Detailed Description
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease characterized by a multitude of symptoms, which greatly reduce the quality of life of patients. In addition to sensory and visual s...
Eligibility Criteria
Inclusion
- diagnosis of multiple sclerosis.
- no acute inflammation during the last 3 months before the experimental intervention.
- no cortisol treatment during the last 3 months before the experimental intervention.
- stable medication during the experimental intervention.
- unrestrained or corrected visual ability.
- ability to read and write short german sentences.
- adequate motor ability to give responses on a keyboard.
- German as main language.
Exclusion
- major depressive symptoms or any further neurological and/or psychiatric disease at experimental intervention.
- standard tDCS exclusion criteria (e.g. cardiac pacemaker, metal implants in head region, etc.)
Key Trial Info
Start Date :
December 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04667221
Start Date
December 8 2020
End Date
December 31 2023
Last Update
May 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medicine Greifswald
Greifswald, Germany, 17489